You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development of a scalable, portable device platform to help objectively monitor the treatment of substance abuse.

    SBC: WAVi Co.            Topic: NIDA

    Abstract Assessing the effectiveness of substance abuse rehabilitation, where high relapse rates create financial and social tolls, is a pressing clinical problem in need of better measurement tools. The ability to identify cognitive changes should improve outcomes but current intake into rehabilitation programs doesn’t typically include cognitive tests. Simple, quick, cost-effective, and object ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid phage-amplified immunoassay for phenotypic UTI diagnosis and antimicrobial susceptibility testing

    SBC: Cobio Diagnostics Inc.            Topic: 400

    Project Summary/Abstract Urinary tract infections (UTIs) are the most common infection type in the U.S., with around 10.5 million infections per year equating to a cost of $3 billion. Of significant concern to the healthcare industry, the number of antibiotic resistant UTIs is increasing at an alarming rate while determining which drugs are effective remains a significant challenge. Current clinic ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Eliminating the human factor from stereotaxic surgeries

    SBC: Popneuron LLC            Topic: 104

    Project Summary: The main goal of this research project is to develop a new line of new stereotaxic devices for small animal research that outperforms existing devices in terms of accuracy, reproducibility, and ease of use. Advancing a tool such as an electrode, injection pipette or optical fiber through a small hole in the cranium, sometimes over long distances, and placing it precisely in a part ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. The Point Powered: A Robust Actuated Prosthetic Finger for Partial Hand Amputation

    SBC: POINT DESIGNS, LLC            Topic: NIBIB

    The Point Powered: A Robust Powered Prosthetic Fingerfor Partial Hand AmputationPROJECT SUMMARY / ABSTRACT The goal of the proposed project is to develop a robust, powered prosthetic finger – the Point Powered – which 1) has an industry leading strength and speed, 2) offers anatomical rotation and flexion, and 3) can be made using advanced metal 3D printing technology. The Point Powered is the ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A New Tool to Rapidly Diagnose Sepsis using Flow Imaging Microscopy and Machine Learning

    SBC: Ursa Analytics            Topic: NIBIB

    Project SummarySepsis is a serious condition induced by an infection, often by a bacterial pathogen, leading to organ damage or even death. Despite numerous advances in medicine over the years, the condition still affects millions of people in both developed and developing countries. In the US, sepsis affects 1.7M and kills over 265,000 people annually. Sepsis mortality rates in developing countri ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD

    SBC: MYCOBACTERIA THERAPEUTICS CORPORATION            Topic: NCCIH

    Project Summary Immunoregulation, i.e., balanced expression of regulatory and effector T cells, is thought to be compromised in modern high-income settings due in part to reduced contact with commensal and environmentally derived bacteria, also known as “old friends”. Failed immunoregulation is thought to be one factor contributing to recent increases in stress-related and chronic inflammatory ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Dissipative Total Disc Replacement for Restoration of Natural Motion for Treatment of Degenerative Disc Disease

    SBC: IMPRESSIO, INC            Topic: NIAMS

    Project Summary Degenerative disc disease is a condition of loss of integrity of the intervertebral disc, and is thought to occur in nearly every person over 60 years old. In many cases, low back pain is associated with the characteristic collapse of disc height as nerves become constricted and biomechanics of the spine change. When the disease progresses to cause significant pain, patients and do ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Proprietary drug to treat radiodermatitis

    SBC: Allander Biotechnologies            Topic: NIAMS

    Summary Radiodermatitis is skin tissue damage that occurs in 95% of cancer patients receiving radiotherapy (RT). Although modern RT, e.g., intensity-modulated RT (IMRT) or stereotactic body RT (SBRT), spares more skin areas from RT damage than regular RT, radiodermatitis is still the major toxicity in skin cancer patients treated with SBRT as well as in other cancer patients treated with regular R ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer

    SBC: Aurora Oncology, Inc.            Topic: 399

    Project Summary/Abstract Bladder cancer causes over 165,000 annual deaths worldwide with 70,000 new cases and 16,000 deaths reported in the US. Treatment of superficial bladder cancer by resection and BCG administration is unsuccessful in 40% of cases with recurrences eventually requiring cystectomy or other aggressive therapy; new therapies are needed. The role of Epidermal Growth Factor Receptor ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a novel product for skin decontamination after exposure to chemical warfare agents

    SBC: Armis Biopharma, Inc.            Topic: 105

    ABSTRACT With the increasing threat of terrorism, the development of countermeasures for the event of a chemical attack on civilians has become a high priority. Mass casualty events in which chemical warfare agents (CWA) would be employed in an attack on a civilian population, are a concrete risk. Because of significant differences between members of the military and civilians, existing countermea ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government